Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-23

STAAR Surgical Co (STAA)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$7,522,385
Stephen Farrell total, FY2025
40th
CEO pay percentile vs peers
97:1
CEO-to-median pay ratio
96.28%
Say-on-pay support, latest vote
Companies that benchmark against STAA
18 companies name STAA as a compensation peer

Each company listed discloses STAA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named STAA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Stephen Farrell$580,000$0$6,836,000$0$0$0$106,385$7,522,385
Chief Executive Officer
Warren Foust594,238250,0003,000,0160567,000029,4104,440,664
President and Chief Operating Officer
Nathaniel Sisitsky488,75075,0001,800,0360381,150021,0262,765,962
Chief Legal Officer and Corporate Secretary
Magda Michna516,81901,800,0360353,025025,8722,695,752
Chief Development Officer
Deborah Andrews810,17301,400,0160367,53804,6842,582,411
Chief Financial Officer
Thomas Frinzi167,154000001,088,7611,255,915
Former President and Chief Executive Officer
Patrick Williams146,07000000780,871926,941
Former Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Stephen Farrell$7,522,385
Warren Foust4,440,6642,903,6693,250,292+1,536,995
Nathaniel Sisitsky2,765,9622,131,935+634,027
Magda Michna2,695,7522,313,683+382,069
Deborah Andrews2,582,411
Thomas Frinzi1,255,9157,821,21610,220,581−6,565,301
Patrick Williams926,9412,898,8892,816,869−1,971,948

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Magda MichnaChief Development Officer2026-05-08D1,680$27$44,839CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-08D3,4482792,027CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15D1,8773260,195CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15D2,4313277,962CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A7,33100CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15D3,73032119,621CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15A5,23300Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15D1,1183235,854CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A10,99700Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A5,49900Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A2,19900Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-05-151,1001 insider, 1 accrual row
Magda MichnaChief Development Officer2026-05-15A5,49900CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15A5,23300CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15D3,73032119,621CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15A10,46600CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15D1,8653259,811CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A3,66600Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A1,10000CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15D5593217,927CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A14,66200CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A7,33100CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A2,19900CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15D3,75532120,423CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15A10,46600Derivative, Class A CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15D7,46032239,242CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A3,66600CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A14,66200Derivative, Class A CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A7,33100Derivative, Class A CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A7,33100Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A10,99700CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15D5,59532179,432CommonForm 4 ↗
Lilian Y. ZhouDirector2026-06-12A3,5302899,865CommonForm 4 ↗
Arthur C. ButcherDirector2026-06-18A3,70900Derivative, Class A CommonForm 4 ↗
Louis E. SilvermanDirector2026-06-18A10,68300CommonForm 4 ↗
Louis E. SilvermanDirector2026-06-18A6,18200Derivative, Class A CommonForm 4 ↗
Wei JiangDirector2026-06-18A10,68300CommonForm 4 ↗
Lilian Y. ZhouDirector2026-06-18A5,57200Derivative, Class A CommonForm 4 ↗
Wei JiangDirector2026-06-18A6,18200Derivative, Class A CommonForm 4 ↗
Christopher M. WangDirector2026-06-18A11,14500Derivative, Class A CommonForm 4 ↗
Arthur C. ButcherDirector2026-06-18D5,34100Derivative, Class A CommonForm 4 ↗
Neal C. BradsherDirector2026-06-18A11,14500Derivative, Class A CommonForm 4 ↗
Wei JiangDirector2026-06-18D10,68300Derivative, Class A CommonForm 4 ↗
Louis E. SilvermanDirector2026-06-18D10,68300Derivative, Class A CommonForm 4 ↗
Richard T. LeBuhnDirector2026-06-18A11,14500Derivative, Class A CommonForm 4 ↗
Arthur C. ButcherDirector2026-06-18A5,34100CommonForm 4 ↗
Arthur C. ButcherDirector2026-06-18A4,45800Derivative, Class A CommonForm 4 ↗
Lilian Y. ZhouDirector2026-06-18A3,09100Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 48 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Magda MichnaChief Development Officer2026-05-08D1,680$27$44,839CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-08D3,4482792,027CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15D1,8773260,195CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15D2,4313277,962CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A7,33100CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15D3,73032119,621CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15A5,23300Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15D1,1183235,854CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A10,99700Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A5,49900Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A2,19900Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A1,10000Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A5,49900CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15A5,23300CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15D3,73032119,621CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15A10,46600CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15D1,8653259,811CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A3,66600Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A1,10000CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15D5593217,927CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A14,66200CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A7,33100CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A2,19900CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15D3,75532120,423CommonForm 4 ↗
Deborah AndrewsInterim Co-CEO and CFO2026-05-15A10,46600Derivative, Class A CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15D7,46032239,242CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A3,66600CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A14,66200Derivative, Class A CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A7,33100Derivative, Class A CommonForm 4 ↗
Warren FoustInterim Co-CEO and Pres. & COO2026-05-15A7,33100Derivative, Class A CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15A10,99700CommonForm 4 ↗
Magda MichnaChief Development Officer2026-05-15D5,59532179,432CommonForm 4 ↗
Lilian Y. ZhouDirector2026-06-12A3,5302899,865CommonForm 4 ↗
Arthur C. ButcherDirector2026-06-18A3,70900Derivative, Class A CommonForm 4 ↗
Louis E. SilvermanDirector2026-06-18A10,68300CommonForm 4 ↗
Louis E. SilvermanDirector2026-06-18A6,18200Derivative, Class A CommonForm 4 ↗
Wei JiangDirector2026-06-18A10,68300CommonForm 4 ↗
Lilian Y. ZhouDirector2026-06-18A5,57200Derivative, Class A CommonForm 4 ↗
Wei JiangDirector2026-06-18A6,18200Derivative, Class A CommonForm 4 ↗
Christopher M. WangDirector2026-06-18A11,14500Derivative, Class A CommonForm 4 ↗
Arthur C. ButcherDirector2026-06-18D5,34100Derivative, Class A CommonForm 4 ↗
Neal C. BradsherDirector2026-06-18A11,14500Derivative, Class A CommonForm 4 ↗
Wei JiangDirector2026-06-18D10,68300Derivative, Class A CommonForm 4 ↗
Louis E. SilvermanDirector2026-06-18D10,68300Derivative, Class A CommonForm 4 ↗
Richard T. LeBuhnDirector2026-06-18A11,14500Derivative, Class A CommonForm 4 ↗
Arthur C. ButcherDirector2026-06-18A5,34100CommonForm 4 ↗
Arthur C. ButcherDirector2026-06-18A4,45800Derivative, Class A CommonForm 4 ↗
Lilian Y. ZhouDirector2026-06-18A3,09100Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Warren FoustRSU2025-03-1458,651$2,000,000
Magda MichnaRSU2025-03-1443,9891,500,024
Stephen FarrellRSU2025-02-26200,0006,836,000
Deborah AndrewsPSU2025-06-2541,86741,8661,400,016
Nathaniel SisitskyRSU2025-03-1443,9891,500,024
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Warren Foust$2,000,000$0$00.0%
Magda Michna1,500,024000.0%
Stephen Farrell6,836,000000.0%
Deborah Andrews01,400,0160100.0%
Nathaniel Sisitsky1,500,024000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Warren FoustRSU87,977$2,076,257
Nathaniel SisitskyPSU52,7871,245,773
Stephen FarrellRSU200,0004,720,000
Thomas FrinziRSU29,269690,748
Warren FoustRSU16,350385,860
Magda MichnaPSU52,7871,245,773
Magda MichnaRSU12,356291,602
Nathaniel SisitskyRSU7,312172,563
Deborah AndrewsPSU41,866988,038
Stephen FarrellRSU92121,736
Nathaniel SisitskyOption13,28732.14
Warren FoustRSU6,777159,937
Magda MichnaOption6,91737.64
Nathaniel SisitskyOption6,52437.64
Warren FoustOption5,21867.63
Magda MichnaOption3,60567.63
Magda MichnaRSU52,7871,245,773
Nathaniel SisitskyRSU52,7871,245,773
Warren FoustPSU87,9772,076,257
Stephen FarrellPSU200,0004,720,000
Deborah AndrewsRSU41,867988,061
Thomas FrinziRSU24,796585,186
Magda MichnaRSU4,683110,519
Nathaniel SisitskyRSU11,654275,034
Warren FoustOption9,15337.64
05

Incentive-plan design — the Compensation Discussion & Analysis

Targeting awards that will attract, retain, and motivate outstanding leaders that drive positive business results; Rewarding achievement of a mix of near, medium, and longer-term business objectives designed to build and increase shareholder value; Paying for performance and aligning the interests of management with Company shareholders

CEO STI target (% of salary)100%
CEO LTI target (% of salary)
Independent consultantSemler Brossy
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1839,737,3851,454,18682,75096.28%Passed
20252025-06-1841,130,6901,049,89724,66797.45%Passed
20242024-06-2133,982,5986,912,21326,83583.04%Passed
20232023-06-1535,577,4951,838,48674,93894.9%Passed
20222022-06-1637,903,9861,514,494219,26995.63%Passed
20212021-06-2435,061,105929,45755,18197.27%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1896.28%a
20252025-06-1897.45%b
20242024-06-2183.04%c

a. Approved under the standard stated in the filing — “Compensation of named executive officers ("say-on-pay") For Majority of votes present in person or by proxy and entitled to vote thereon Abstentions have the effect of a vote against;”.

b. Approved under the standard stated in the filing — “Compensation of named executive officers ("say-on-pay") For Majority of votes present in person or by proxy and entitled to vote thereon Abstentions have the effect of a vote against;”.

c. Approved under the standard stated in the filing — “Compensation of named executive officers ("say-on-pay") For Majority of votes present in person or by proxy and entitled to vote thereon Abstentions have the effect of a vote against;”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)97 : 1
CEO total compensation$8,646,501
Median employee compensation$89,344
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Wei JiangNot independent · Audit$58,036$180,009$0$1,298,002$1,536,047
Lilian Y. ZhouIndependent · Audit (Chair) · Nominating/Governance80,962220,0090147,600448,571
Elizabeth Yeu, M.DIndependent · Audit · Compensation · Nominating/Governance (Chair) · Not standing for re-election · Departed during FY113,58589,99690,0050293,586
Louis E. SilvermanIndependent · Compensation (Chair) · Nominating/Governance47,500180,00927,2780254,787
Arthur C. ButcherIndependent · Audit63,39389,99690,0050243,394
Aimee S. WeisnerIndependent · Compensation · Not standing for re-election · Departed during FY31,799031,799
Stephen C. FarrellEmployee director · Audit · Not standing for re-election · Departed during FY00000
Thomas G. FrinziEmployee director · Not standing for re-election · Departed during FY00000
K. Peony Yu, M.DIndependent · Not standing for re-election · Departed during FY000000
Neal C. BradsherIndependent · Board Chair · Nominating/Governance (Chair) · Partial-year service · Newly elected000000
Christopher M. WangIndependent · Audit · Compensation · Nominating/Governance · Partial-year service · Newly elected000000
Richard T. LeBuhnIndependent · Compensation · Partial-year service · Newly elected000000
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$180,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)15,000 / 15,000 / 15,000
Stock ownership guideline3x base annual cash retainer (directors); 3x annual base salary (CEO)
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$395,275
Equity awards (grant-date value)$540,010
All other compensation$1,445,602
Total cost of the board$2,380,887

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies STAAR Surgical Co names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including STAAR Surgical Co.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Merit Medical Systems, Inc.2025Fred Lampropoulos$1,890,000$9,313,606$0$1,882,894$13,755,143
2Glaukos Corp.2025Thomas Burns850,0007,649,9473,527,497012,034,087
3iRhythm Technologies, Inc.2025Quentin Blackford700,0038,919,45701,350,00011,003,163
4Alphatec Holdings, Inc.2025Patrick Miles762,0008,859,6500600,00010,260,507
5Avanos Medical, Inc.2025David Pacitti751,7057,000,00001,148,6679,469,803
6AtriCure, Inc.2025Michael Carrel828,4397,203,47801,171,7039,217,620
7AxoGen, Inc.2025Michael Dale775,8657,342,8950906,1339,047,454
8Inspire Medical Systems, Inc.2025Timothy Herbert750,5725,999,6550961,5577,711,784
9UFP Technologies, Inc.2025R. Jeffrey Bailly789,0005,377,49901,260,9347,648,440
10STAAR Surgical Co2025Stephen Farrell580,0006,836,000007,522,385
11Artivion, Inc.2025J. Patrick Mackin835,1455,006,9900991,3686,883,108
12Tandem Diabetes Care, Inc.2025John Sheridan790,5835,367,7960674,0906,858,503
13Inari Medical, Inc.2023Andrew Hykes700,0002,606,744937,488826,0005,083,365
14RxSight, Inc.2025Ron Kurtz630,62503,816,530202,9354,650,661
15LeMaitre Vascular, Inc.2025George LeMaitre806,3471,050,0001,050,000680,0153,780,990
16Penumbra, Inc.2025Adam Elsesser850,000000851,621

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
STAAR Surgical Co135%RSU 50 · PSU 50NoSemler Brossy
Alphatec Holdings, Inc.157%PSU 50 · RSU 50NoCompensia, Inc.
Artivion, Inc.118.7%PSU 50 · RSU 50NoWillis Towers Watson
AtriCure, Inc.141%PSU 70 · RSU 30NoKorn Ferry
Avanos Medical, Inc.139%PSU 50 · RSU 25 · Options 25NoMeridian Compensation Partners
AxoGen, Inc.116.79%PSU 50 · RSU 50NoAon
Glaukos Corp.177.5%PSU 50NoFrederic W. Cook & Co., Inc.
Inari Medical, Inc.118%RSU 75 · Options 25not disclosedFW Cook
Inspire Medical Systems, Inc.111.4%PSU 50 · RSU 50NoAon
iRhythm Technologies, Inc.173%PSU 50 · RSU 50NoAon (January 1 to May 28) and Mercer (May 29 forward)
LeMaitre Vascular, Inc.144%Options 50 · RSU 25 · PSU 25Nonot disclosed
Merit Medical Systems, Inc.124.53%PSU 60 · RSU 40Yes — Relative Total Shareholder Return (rTSR)Pearl Meyer & Partners, LLC
Penumbra, Inc.not disclosednot disclosedNoCompensia
RxSight, Inc.32.18%Options 100not disclosedAon Human Capital Solutions
Tandem Diabetes Care, Inc.87%PSU 50 · RSU 50Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027WTW
UFP Technologies, Inc.152%not disclosedNoPearl Meyer

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at STAAR Surgical Co in fiscal 2025?
As disclosed, the highest-paid executive at STAAR Surgical Co in fiscal 2025 was Stephen Farrell, Chief Executive Officer, with total compensation of $7,522,385.
How does STAAR Surgical Co's chief executive pay compare to its disclosed peer group?
The filing shows that the CEO's pay placed him at the 40th percentile of the disclosed peer group.
What is STAAR Surgical Co's CEO-to-median employee pay ratio?
As disclosed, the CEO-to-median employee pay ratio was 97:1.
How did shareholders vote on STAAR Surgical Co's executive compensation?
The filing shows that shareholder support for the executive compensation plan was 96.28%.
How much does STAAR Surgical Co spend in total on board compensation for fiscal 2025?
As disclosed, total board compensation for fiscal 2025 was $2,380,887.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Stephen FarrellDEF 14A2026-05-040000718937-26-000015Section “Summary Compensation Table”. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486
2Section 01, Warren FoustDEF 14A2026-05-040000718937-26-000015Section “Summary Compensation Table”. As printed: 4,440,664. Filing ↗machine: r7 · c16 · span 1071122–1071131
3Section 01, Nathaniel SisitskyDEF 14A2026-05-040000718937-26-000015Section “Summary Compensation Table”. As printed: 2,765,962. Filing ↗machine: r13 · c16 · span 1109669–1109678
4Section 01, Magda MichnaDEF 14A2026-05-040000718937-26-000015Section “Summary Compensation Table”. As printed: 2,695,752. Filing ↗machine: r10 · c16 · span 1090527–1090536
5Section 01, Deborah AndrewsDEF 14A2026-05-040000718937-26-000015Section “Summary Compensation Table”. As printed: 2,582,411. Filing ↗machine: r5 · c16 · span 1058392–1058401
6Section 01, Thomas FrinziDEF 14A2026-05-040000718937-26-000015Section “Summary Compensation Table”. As printed: 1,255,915. Filing ↗machine: r16 · c16 · span 1128884–1128893
7Section 01, Patrick WilliamsDEF 14A2026-05-040000718937-26-000015Section “Summary Compensation Table”. As printed: 926,941. Filing ↗machine: r19 · c16 · span 1148487–1148494
8Section 03, Warren Foust RSUDEF 14A2026-05-040000718937-26-000015Section “COMPENSATION OF DIRECTORS” · grants of plan-based awards table. Filing ↗machine: t77 · r5 · c5 · span 911849–911858
9Section 03, Magda Michna RSUDEF 14A2026-05-040000718937-26-000015Section “COMPENSATION OF DIRECTORS” · grants of plan-based awards table. Filing ↗machine: t77 · r6 · c5 · span 918019–918028
10Section 03, Stephen Farrell RSUDEF 14A2026-05-040000718937-26-000015Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t86 · r3 · c8 · span 1042611–1042620
11Section 03, Deborah Andrews PSUDEF 14A2026-05-040000718937-26-000015Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t86 · r5 · c8 · span 1055528–1055537
12Section 03, Nathaniel Sisitsky RSUDEF 14A2026-05-040000718937-26-000015Section “COMPENSATION OF DIRECTORS” · grants of plan-based awards table. Filing ↗machine: t77 · r7 · c5 · span 924201–924210
13Section 07, pay ratioDEF 14A2026-05-040000718937-26-000015Section “CEO Pay Ratio”. As printed: 97 : 1. Filing ↗machine: span 1931849–1931853
14Section 08, Wei JiangDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 1,536,047. Filing ↗machine: t49 · r4 · c13 · span 572869–572878
15Section 08, Lilian Y. ZhouDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 448,571. Filing ↗machine: t49 · r8 · c13 · span 595876–595883
16Section 08, Elizabeth Yeu, M.DDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 293,586. Filing ↗machine: t49 · r7 · c13 · span 590208–590215
17Section 08, Louis E. SilvermanDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 254,787. Filing ↗machine: t49 · r5 · c13 · span 578717–578724
18Section 08, Arthur C. ButcherDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 243,394. Filing ↗machine: t49 · r3 · c13 · span 567218–567225
19Section 08, Aimee S. WeisnerDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 31,799. Filing ↗machine: t49 · r6 · c2 · span 580245–580251
20Section 08, Stephen C. FarrellDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 0. Filing ↗
21Section 08, Thomas G. FrinziDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 0. Filing ↗
22Section 08, K. Peony Yu, M.DDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 0. Filing ↗
23Section 08, Neal C. BradsherDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 0. Filing ↗
24Section 08, Christopher M. WangDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 0. Filing ↗
25Section 08, Richard T. LeBuhnDEF 14A2026-05-040000718937-26-000015Section “Director Compensation”. As printed: 0. Filing ↗
26Section 02, Magda Michna 2026-05-08Form 42026-05-120001731487-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Warren Foust 2026-05-08Form 42026-05-120001970778-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Deborah Andrews 2026-05-15Form 42026-05-190001325697-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Deborah Andrews 2026-05-15Form 42026-05-190001325697-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Deborah Andrews 2026-05-15Form 42026-05-190001325697-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Deborah Andrews 2026-05-15Form 42026-05-190001325697-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Deborah Andrews 2026-05-15Form 42026-05-190001325697-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Deborah Andrews 2026-05-15Form 42026-05-190001325697-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Warren Foust 2026-05-15Form 42026-05-190001970778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Magda Michna 2026-05-15Form 42026-05-190001731487-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Lilian Y. Zhou 2026-06-12Form 42026-06-150001193125-26-271092Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Arthur C. Butcher 2026-06-18Form 42026-06-220001678249-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Louis E. Silverman 2026-06-18Form 42026-06-220001249935-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Louis E. Silverman 2026-06-18Form 42026-06-220001249935-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Wei Jiang 2026-06-18Form 42026-06-220001867980-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Lilian Y. Zhou 2026-06-18Form 42026-06-220002003105-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Wei Jiang 2026-06-18Form 42026-06-220001867980-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Christopher M. Wang 2026-06-18Form 42026-06-230000921895-26-001649Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Arthur C. Butcher 2026-06-18Form 42026-06-220001678249-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Neal C. Bradsher 2026-06-18Form 42026-06-220000919574-26-004068Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Wei Jiang 2026-06-18Form 42026-06-220001867980-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Louis E. Silverman 2026-06-18Form 42026-06-220001249935-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Richard T. LeBuhn 2026-06-18Form 42026-06-220000919574-26-004069Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Arthur C. Butcher 2026-06-18Form 42026-06-220001678249-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Arthur C. Butcher 2026-06-18Form 42026-06-220001678249-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Lilian Y. Zhou 2026-06-18Form 42026-06-220002003105-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
74Section 06, 2026 voteForm 8-K2026-06-220000718937-26-000029Item 5.07 · say-on-pay result. As reported: 96.28% (votes for as printed: 39,737,385). Filing ↗
75Section 06, 2025 voteForm 8-K2025-06-180000950170-25-087967Item 5.07 · say-on-pay result. As reported: 97.45% (votes for as printed: 41,130,690). Filing ↗
76Section 06, 2024 voteForm 8-K2024-06-210000950170-24-076303Item 5.07 · say-on-pay result. As reported: 83.04% (votes for as printed: 33,982,598). Filing ↗
77Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
78Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
79Section 09b board cost (computed)ComputedcomputedCash 395,275 + equity 540,010 + all other 1,445,602 = 2,380,887, summed across the director compensation table rows.machine: formula: Σ = 2,380,887
80Merit Medical Systems, Inc., Section 10b CEO totalDEF 14A2026-03-310000856982-26-000013CEO total compensation as printed in Merit Medical Systems, Inc.'s own proxy. As printed: 13,755,143. Filing ↗machine: r21 · c8 · span 1277869–1277879
81Glaukos Corp., Section 10b CEO totalDEF 14A2026-04-160001193125-26-157829CEO total compensation as printed in Glaukos Corp.'s own proxy. As printed: 12,034,087. Filing ↗machine: t93 · r6 · c38 · span 1876942–1876952
82iRhythm Technologies, Inc., Section 10b CEO totalDEF 14A2026-04-170001388658-26-000030CEO total compensation as printed in iRhythm Technologies, Inc.'s own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508
83Alphatec Holdings, Inc., Section 10b CEO totalDEF 14A2026-04-290001193125-26-191867CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158
84Avanos Medical, Inc., Section 10b CEO totalDEF 14A2026-03-120001104659-26-027106CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. Filing ↗machine: r1 · c53 · span 1674377–1674386
85AtriCure, Inc., Section 10b CEO totalDEF 14A2026-04-060001323885-26-000010CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373
86AxoGen, Inc., Section 10b CEO totalDEF 14A2026-04-290000805928-26-000057CEO total compensation as printed in AxoGen, Inc.'s own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318
87Inspire Medical Systems, Inc., Section 10b CEO totalDEF 14A2026-03-200001140361-26-010490CEO total compensation as printed in Inspire Medical Systems, Inc.'s own proxy. As printed: 7,711,784. Filing ↗machine: r2 · c25 · span 1164868–1164877
88UFP Technologies, Inc., Section 10b CEO totalDEF 14A2026-04-300001628280-26-028710CEO total compensation as printed in UFP Technologies, Inc.'s own proxy. As printed: 7,648,440. Filing ↗machine: t11 · r3 · c21 · span 261984–261993
89STAAR Surgical Co (subject), Section 10b CEO totalDEF 14A2026-05-040000718937-26-000015CEO total compensation as printed in STAAR Surgical Co's own proxy. As printed: 7,522,385. Filing ↗machine: r3 · c16 · span 1045477–1045486
90Artivion, Inc., Section 10b CEO totalDEF 14A2026-04-010001999371-26-007510CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882
91Tandem Diabetes Care, Inc., Section 10b CEO totalDEF 14A2026-04-070001438133-26-000034CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. Filing ↗machine: r3 · c27 · span 866963–866972
92Inari Medical, Inc., Section 10b CEO totalDEF 14A2024-03-130001193125-24-066805CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517
93RxSight, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187240CEO total compensation as printed in RxSight, Inc.'s own proxy. As printed: 4,650,661. Filing ↗machine: t20 · r4 · c24 · span 978530–978539
94LeMaitre Vascular, Inc., Section 10b CEO totalDEF 14A2026-04-140001193125-26-153877CEO total compensation as printed in LeMaitre Vascular, Inc.'s own proxy. As printed: 3,780,990. Filing ↗machine: span 564038–564047
95Penumbra, Inc., Section 10b CEO totalDEF 14A2026-04-290001321732-26-000010CEO total compensation as printed in Penumbra, Inc.'s own proxy. As printed: 851,621. Filing ↗machine: span 424797–424804
96Section 10a, Inspire Medical Systems, Inc. reciprocityDEF 14A0001140361-26-010490Inspire Medical Systems, Inc. names STAAR Surgical Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
97Section 10a, Avanos Medical, Inc. reciprocityDEF 14A0001104659-26-027106Avanos Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include STAAR Surgical Co. Filing ↗
98Section 10a, AxoGen, Inc. reciprocityDEF 14A0000805928-26-000057AxoGen, Inc. names STAAR Surgical Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
99Section 10a, Alphatec Holdings, Inc. reciprocityDEF 14A0001193125-26-191867Alphatec Holdings, Inc. names STAAR Surgical Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
100Section 10a, Penumbra, Inc. reciprocityDEF 14A0001321732-26-000010Penumbra, Inc.'s most recent proxy was read; its disclosed peer group does not include STAAR Surgical Co. Filing ↗
101Section 10a, AtriCure, Inc. reciprocityDEF 14A0001323885-26-000010AtriCure, Inc. names STAAR Surgical Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
102Section 10a, Merit Medical Systems, Inc. reciprocityDEF 14A0000856982-26-000013Merit Medical Systems, Inc.'s most recent proxy was read; its disclosed peer group does not include STAAR Surgical Co. Filing ↗
103Section 10a, RxSight, Inc. reciprocityDEF 14A0001193125-26-187240RxSight, Inc.'s most recent proxy was read; its disclosed peer group does not include STAAR Surgical Co. Filing ↗
104Section 10a, Inari Medical, Inc. reciprocityDEF 14A0001193125-24-066805Inari Medical, Inc.'s most recent proxy was read; its disclosed peer group does not include STAAR Surgical Co. Filing ↗
105Section 10a, UFP Technologies, Inc. reciprocityDEF 14A0001628280-26-028710UFP Technologies, Inc. names STAAR Surgical Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
106Section 10a, Artivion, Inc. reciprocityDEF 14A0001999371-26-007510Artivion, Inc. names STAAR Surgical Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
107Section 10a, Glaukos Corp. reciprocityDEF 14A0001193125-26-157829Glaukos Corp. names STAAR Surgical Co in its own disclosed peer group (read from its most recent proxy). Filing ↗
108Section 10a, iRhythm Technologies, Inc. reciprocityDEF 14A0001388658-26-000030iRhythm Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include STAAR Surgical Co. Filing ↗
109Section 10a, Tandem Diabetes Care, Inc. reciprocityDEF 14A0001438133-26-000034Tandem Diabetes Care, Inc. names STAAR Surgical Co in its own disclosed peer group (read from its most recent proxy). Filing ↗